Titlebook: Cell and Gene Therapies; Miguel-Angel Perales,Syed A. Abutalib,Catherine Bo Book 2019 Springer Nature Switzerland AG 2019 Chimeric antigen

objection

迅速飛過

Mesenchymal Stem Cells: From Bench to Bedside and Backs the treatment of graft-versus-host disease (GvHD) and marrow failure. The initial studies confirmed the infusional safety of MSC given to HCT recipients and have paved the way for subsequent clinical research. Today, more than a decade later, the potential of MSC to improve outcomes after allogene

思想流動(dòng)

Gene Therapy for Neoplastic Hematology in Transplant Settingcide gene therapies, gene suppression, or oncolytic viral and non-viral therapies. In this chapter, we will review the historical context of gene therapy and cellular engineering development for the treatment of hematological malignancies and, particularly, in the setting of hematopoietic cell trans

ticlopidine

Gene Therapy for Nonmalignant Hematologyn of gene-editing platforms, including zinc-finger nuclease (ZFN), transcription activator-like effector nucleases (TALEN), and clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9, offer exciting prospective strategies for further improving gene therapy by targeting the repair of

半身雕像

https://doi.org/10.1057/978-1-137-57085-7heless, the attractions of a component therapy approach to HCT are many including but not limited to (1) T-cell depletion by selection of CD34. cells, which can reduce GvHD, and (2) infused donor lymphocytes which can improve engraftment and treat leukemic relapse. Careful studies in the 1990s deter

induct

擦試不掉

發(fā)現(xiàn)

牙齒

,Conclusion: The Ombuds as “Third Way”,the deficiencies in viral immunity post-transplant. In this review, we begin by detailing the advances made in producing single-virus-specific T cells, in particular for CMV and EBV, and then proceed to describe the progress in developing multi-virus-specific T cells and in broadening the repertoire

誘拐